Αποτελέσματα Αναζήτησης
28 Αυγ 2024 · mRNA-1608 vaccine candidate is under development for the prevention of Herpes simplex virus (HSV-2) Infections such as genital herpes. The vaccine candidate is an mRNA vaccine developed based on mRNA technology platform. It is administered through intramuscular route.
5 Ιουν 2015 · Admedus Limited (ASX:AHZ) today provided a progress update for its Herpes Simplex 2 (HSV-2) Phase II study for its therapeutic vaccine programme. Participants initially enrolled in the study have now started receiving their 2nd dose (vaccination) of the therapeutic vaccine, with the study progressing well.
5 Μαρ 2024 · A leading global vaccine developer has announced that their investigational vaccine candidate for Herpes Simplex Virus (HSV) is undergoing a phase 1/2 clinical trial for the first time in Europe, England, and the United States.
3 Μαΐ 2017 · Admedus Limited (ASX: AHZ) today announced the final results from its Phase IIa Herpes Simplex (HSV-2) vaccine study. The trial reached its primary endpoint of safety, with a positive immune response to the vaccine seen in most subjects.
7 Δεκ 2021 · Within this article, we will review the current guidelines for the treatment of herpes simplex infections, our understanding of the immunological pathways involved, and novel vaccine candidates in development. Keywords: DNA vaccine; herpes simplex virus type 1; herpes simplex virus type 2; live attenuated vaccine; mRNA vaccine; subunit vaccine;
An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs. J. Virol. 2013;87:3930–3942. doi: 10.1128/JVI.02745-12.
The Phase 2 study, in which volunteers were randomized 2:1 to vaccine or placebo, was conducted in 261 healthy HSV-2 seropositive adults with a self-reported history of 4 to 9 recurrences per year. Unfortunately, the annualized recurrence rate in the placebo group was lower than what was expected, and, thus, the trial did not have sufficient ...
